Concepedia

Zhuli Wu

ZW

Statistics

Publications

4

Citations

79

H-Index

4

Active since

2017

Affiliations

Fosun Pharma (China)(Current)

Chinese Academy of Medical Sciences & Peking Union Medical College

Fudan University Shanghai Cancer Center

Sun Yat-sen University Cancer Center

Sun Yat-sen University

Zhuli Wu is an author at Fosun Pharma (China) specializing in medicine, oncology, and pharmacology.

Publications per year

2017–2024

4

Publications

4

A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapy-naïve patients with mCRPC in China, Malaysia, Thailand and Russia

Dingwei Ye, Fangjian Zhou, Keji Xie et al. · Asian journal of urology · 2017 · 30 citations · Full text

, , +17

HER2-targeting antibody drug conjugate FS-1502 in HER2-expressing metastatic breast cancer: a phase 1a/1b trial

Qiao Li, Ying Cheng, Zhongsheng Tong et al. · Nature Communications · 2024 · 20 citations · Full text

, , +17

A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma

Lili Mao, Jun Guo, Lingjun Zhu et al. · European Journal of Cancer · 2022 · 17 citations

, , +15

Phase 1 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1-related unresectable plexiform neurofibromas

Xiaojie Hu, Wenbin Li, Kang Zeng et al. · BMC Medicine · 2023 · 12 citations · Full text

, , +17

1–4 of 4